Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 64% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 4 institutions in 2 countries.
Jennifer L HopeDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands; jhope@sbpdiscovery.org p.katsikis@erasmusmc.nl.ORCID 0000-0002-2363-5442
Manzhi ZhaoDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-9410-035X
Christopher J StairikerDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-8503-0983
Caoimhe H KiernanDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Alison J CareyDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA.ORCID 0000-0001-7610-5659
Yvonne M MuellerDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-4654-7509
Marjan van MeursDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Inge Brouwers-HaspelsDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-4492-446X
Dennis C OteroAging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.ORCID 0000-0001-5149-8062
Eun-Ah BaeAging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.ORCID 0000-0002-9413-2543
Hannah A FasoAging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.ORCID 0000-0002-2884-8746
Alex MaasDepartment of Cell Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Hans de LooperDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-3416-7581
Paolo M FortinaDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA; and.ORCID 0000-0002-5898-2081
Isidore RigoutsosComputational Medicine Center, Thomas Jefferson University, Philadelphia, PA.ORCID 0000-0003-1529-8631
Linda M BradleyAging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.ORCID 0000-0002-8697-8565
Stefan J ErkelandDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-1019-7957
Peter D KatsikisDepartment of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands; jhope@sbpdiscovery.org p.katsikis@erasmusmc.nl.ORCID 0000-0001-7690-5218
Erasmus MC · NLSanford Burnham Prebys Medical Discovery Institute · USThomas Jefferson University · USDrexel University · US
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
NCI NIH HHS P30 CA030199Worldwide Cancer Research 16-1153
6 · The paper itself
Abstract
MicroRNAs (miRNAs/miRs) are small, endogenous noncoding RNAs that are important post-transcriptional regulators with clear roles in the development of the immune system and immune responses. Using miRNA microarray profiling, we characterized the expression profile of naive and in vivo generated murine effector antiviral CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
MicroRNA-139 Expression Is Dispensable for the Generation of Influenza-Specific CD8 · full record | OpenQuestion